Ahmad Abubaker, MD
@A_AbubakerMD
Followers
139
Following
280
Media
14
Statuses
79
🇯🇴MD | Surgeon scientist in the making |#ThyroidCancer #HeadandNeckCancer #PDX #treatment_resistance #Innovation @MDAndersonNews.
Houston, TX
Joined July 2024
Tracheal resection is one of the most complex and high-risk surgeries for #thyroidcancer. Here, we share indications, complications, and outcomes of resections up to 9 rings with end-to-end anastomosis. @MDAndersonNews
https://t.co/XxfCsgLQoS
onlinelibrary.wiley.com
Background Segmental tracheal resection is rarely needed for advanced thyroid cancer but is among the most complex, high-risk thyroid surgeries. Methods Retrospective study of patients undergoing ...
0
1
11
So great to be back at @myESMO to present our trial-in-progress @NRGonc #HN014 testing neoadjuvant #immunotherapy in advanced, resectable #skin #CSCC cancer @Regeneron @CDNCancerTrials @TROGfightcancer #OncSurgery @MDAndersonNews #ESMO2025
0
7
22
Every step I’ve made so far was filled with uncertainties and challenges, yet somehow, everything managed to fall into place effortlessly. Now I carry a deep faith that things will continue to work out in ways I could never anticipate.
0
0
5
Another wonderful #atathyroid2025 meeting with a strong @MDAndersonNews representation! Especially proud of @A_AbubakerMD and @JorgeArpiP for their strong work presenting the team’s translational and clinical data! Already looking forward to next year’s meeting!
1
5
29
💡Should you have questions, suggestions, or need a copy of the poster don’t hesitate to 📩 us.
1
0
1
📌 Preclinical evaluation of a promising novel pan-RAF inhibitor on our robust preclinical models as a single agent: 👉🏼 JZP815 alone is an efficacious inhibitor in BRAF/RAS mutant ATC PDX/cell line models 👉🏼JZP815 alone had minimal in-vivo toxicity
1
0
1
Presenting our work @AmThyroidAssn 2025 meeting today: 📌Isthmus confined PTC, a surgical comparative analysis: 👉🏼 Isthmusectomy had no significant difference from more extensive surgeries in disease outcomes 👉🏼 Isthmusectomy significantly decreased postop adverse events
2
0
6
👨⚕️ & 🧬 balance
Perks of working @MDAndersonNews —> opportunity to meet and greet the dozens of scholars from around the 🌎 coming for observerships within our H&N dept. Throwback to this past June where we had a Mediterranean gathering on the OR bridge along with star researcher @A_AbubakerMD!
1
0
6
Perks of working @MDAndersonNews —> opportunity to meet and greet the dozens of scholars from around the 🌎 coming for observerships within our H&N dept. Throwback to this past June where we had a Mediterranean gathering on the OR bridge along with star researcher @A_AbubakerMD!
4
1
35
Thrilled to share that I’ve been awarded the 2025 ATA Trainee Grant to present my abstracts next month! Small victories feel even sweeter when fueled by hard work and dedication Stay tuned for some exciting and insightful data on Papillary and Anaplastic Thyroid Cancers #ATA_2025
3
4
30
Proud mentor moment. ⭐️⭐️Star mentee @MuntaserZy presenting our work on ICI and SOT at the #ASCO2025
1
0
21
Dr. Anastasios Maniakas presents a global Phase III study testing ASP-1929 photoimmunotherapy combined with pembrolizumab vs standard care in locoregional recurrent head and neck cancer. This novel approach uses light-activated therapy to boost immune response and improve
0
2
7
“Neoadjuvant pembrolizumab in combination with dabrafenib and trametinib should be considered a new standard of care for Stage IV BRAF V600E-mutated anaplastic thyroid cancer,” says our @MarkZafereoMD at #ASCO25. Read more about this practice-changing research:
1
5
20
Meet our experts in booth 10059 to talk about anaplastic thyroid cancer and the evolving role of targeted therapies. Stop by Monday, June 2 at 3 p.m. to join the conversation. Learn more about our specialized clinic: https://t.co/THUDkqrE0h
#ASCO25 #EndCancer (6/6) @SHamidi_MD
0
2
6
Adjuvant Cemiplimab better than Placebo in High-Risk Cutaneous SCC, giving more options for patients. Given that KN630 was negative in a similar, but not identical study group (c-post has higher risk pts), an important lesson in trial design. @NEJM
nejm.org
Patients who have cutaneous squamous-cell carcinoma with high-risk features are at risk for recurrence after definitive local therapy. The benefit of systemic adjuvant therapy options has not been ...
1
2
12
Congratulations to the #C-POST team!!! Huge step forward for patients with high risk, resected #cscc #skin #cancer @Regeneron @TROGfightcancer @ASCOPost @NEJM
1
4
18
Excited to share that my mentee @moathalbliwi from @CleClinicMD will be presenting at #ASCO2025 on how obesity affects immune therapy outcomes — tackling the intriguing obesity paradox. Big work ahead!
3
6
54
Great time joining the @univ_indonesia Faculty of Medicine @Medicine_UI and the Division of Oncologic #OTLHNS sharing my experience in managing locoregionally advanced #headandneckcancer. Thank you for the warm welcome Drs. Adham and Mayangsari and the Indonesia-wide attendees!
0
1
3
Now our work is available on Cancer Research 👇🏻: 1- https://t.co/wFNUVMkDg0 2- https://t.co/mQa2zrxvuT And always you are very welcomed to check my updates and recent works on Research gate: https://t.co/kQnkveuEtg
researchgate.net
My research primarily focuses on the development of preclinical models and experimental approaches to evaluate novel therapeutic agents for Anaplastic Thyroid Carcinoma and Head & Neck Squamous Cell...
0
2
5